Millions of people worldwide suffer from chronic wounds that fail to heal, often due to diabetes, poor circulation, or pressure. These wounds can lead to pain, infection, and even amputation, with current treatments only managing symptoms rather than addressing the root cause.
New research suggests that a molecule called MC1R, best known for its role in red hair and fair skin, may be key to healing. The study found that MC1R is disrupted in chronic wounds, and stimulating it can reduce inflammation and restart the healing process.
MC1R is present in various skin cells, including immune cells and those that form the outer layer and scar tissue. It has anti-inflammatory roles in other conditions, such as arthritis, prompting researchers to investigate its involvement in wound healing.
Analysis of human tissue from diabetic foot ulcers, venous leg ulcers, and pressure ulcers revealed a common imbalance in MC1R and its partner molecule POMC. Experiments on mice with non-functional MC1R showed slow-healing wounds with persistent inflammation, similar to human chronic wounds.
Applying a topical drug that activates MC1R in a new mouse model of chronic ulcers significantly improved healing. It reduced fluid leakage, increased blood vessel growth, and helped the skin close over the wound. The treatment also reduced inflammatory structures called neutrophil extracellular traps.
These findings suggest that targeting MC1R could lead to new treatments for chronic wounds, which are becoming more common with rising rates of diabetes and ageing. Even small improvements in healing could greatly benefit patients and reduce healthcare costs.
